Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 8/20 | 0.49 |
| ▸ | NPC1 | O15118 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8056593 | 0.92 | ABCB1 (0.50) | ABCB1RAB9ANPC1MAPTHSP90AA1 | |
| SCHEMBL17295921 | 0.90 | HDAC3 (0.52) | ABCB1RAB9ANPC1MAPTHSP90AA1 | |
| SCHEMBL2173142 | 0.88 | HDAC3 (0.51) | ABCB1RAB9ANPC1MAPTHSP90AA1 | |
| SCHEMBL17338697 | 0.88 | ABCB1 (0.53) | ABCB1RAB9ANPC1MAPTHSP90AA1 | |
| SCHEMBL18764846 | 0.86 | ABCB1 (0.51) | ABCB1RAB9ANPC1MAPTHSP90AA1 | |
| SCHEMBL1852466 | 0.84 | HDAC3 (0.52) | ABCB1KMT2AMEN1HDAC3HDAC1 | |
| SCHEMBL19370070 | 0.84 | HDAC3 (0.52) | RAB9ANPC1MAPTHDAC3HDAC1 | |
| SCHEMBL1468200 | 0.83 | HDAC3 (0.51) | ABCB1HDAC3HDAC1HDAC6CYP1A2 | |
| SCHEMBL18764790 | 0.83 | ABCB1 (0.53) | ABCB1RAB9ANPC1MAPTHSP90AA1 | |
| SCHEMBL7376437 | 0.82 | ABCB1 (0.52) | ABCB1RAB9ANPC1MAPTHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695240-A2 | CYCLIC VINYL SULFONE WRN INHIBITORS | Nimbus Wadjet, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024215923-A2 | CYCLIC VINYL SULFONE WRN INHIBITORS | NIMBUS WADJET, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2020064175-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | ANTABIO SAS (FR) | 2020-04-02 | — | — | WO | disclosed |
| EP-3628672-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | Antabio SAS (FR) | 2020-04-01 | — | — | EP | disclosed |
| US-20190031650-A1 | DNA ALKYLATION AND CROSS-LINKING AGENTS AS COMPOUNDS AND PAYLOADS FOR TARGETED THERAPIES | UNIV YALE (US) | 2019-01-31 | — | — | US | disclosed |
| US-6642388-B1 | Room temperature cyclization of thioamide derivative with bromopyruvate without use of bases or molecular sieves in alcohol | ABBOTT GMBH & CO. KG (DE) | 2003-11-04 | — | — | US | disclosed |
| US-6586466-B2 | Enzyme inhibitor for use in the treatment of bone, oral, arthritic, paget's and hypercalcemic diseases | SMITHKLINE BEECHAM CORPORATION | 2003-07-01 | — | — | US | disclosed |
| US-6562842-B2 | Osteoporosis, oral diseases | SMITHKLINE BEECHAM CORPORATION | 2003-05-13 | — | — | US | disclosed |
| EP-0928790-B1 | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 2003-03-05 | — | — | EP | disclosed |
| US-20020173469-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-11-21 | — | — | US | disclosed |
| US-6100282-A | Thiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2000-08-08 | — | — | US | disclosed |
| EP-0669336-B1 | NOVEL CEPHEM DERIVATIVES | MEIJI SEIKA CO (JP) | 2000-05-17 | — | — | EP | disclosed |
| US-6057362-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| US-5998470-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| US-5990101-A | Carbapenem derivatives | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1999-11-23 | — | — | US | disclosed |
| CN-1224718-A | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 1999-08-04 | — | — | CN | disclosed |
| EP-0928790-A1 | Thiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-07-14 | — | — | EP | disclosed |
| US-5663162-A | BACTERICIDES AND ANTIBIOTICS | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1997-09-02 | — | — | US | disclosed |
| EP-0760370-A1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1997-03-05 | — | — | EP | disclosed |
| EP-0669336-A1 | NOVEL CEPHEM DERIVATIVE | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1995-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031650-A1 | DNA ALKYLATION AND CROSS-LINKING AGENTS AS COMPOUNDS AND PAYLOADS FOR TARGETED THERAPIES | PCNA, TOP2B, DCLRE1A | ABCB1 451/4885RAB9A 4377/4885NPC1 4581/4885 |
| US-20020173469-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | ABCB1 954/4885RAB9A 1337/4885NPC1 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.